Mizagliflozin, a selective SGLT1 inhibitor, improves vascular cognitive impairment in a mouse model of small vessel disease

Previously, we showed that sodium/glucose cotransporter 1 (SGLT1) participates in vascular cognitive impairment in small vessel disease. We hypothesized that SGLT1 inhibitors can improve the small vessel disease induced‐vascular cognitive impairment. We examined the effects of mizagliflozin, a selec...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishida, Nanae, Saito, Maki, Sato, Sachiko, Tezuka, Yu, Sanbe, Atsushi, Taira, Eiichi, Hirose, Masamichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480397/
https://www.ncbi.nlm.nih.gov/pubmed/34586752
http://dx.doi.org/10.1002/prp2.869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480397/
https://www.ncbi.nlm.nih.gov/pubmed/34586752
http://dx.doi.org/10.1002/prp2.869

Ejemplares similares